In particular, after a median duration of treatment of 28.1 months, the most frequent adverse events with alectinib were constipation, anemia, fatigue, blood bilirubin increase, peripheral oedema, ALT and AST increase, myalgia, nausea and diarrhea [9]. The gene discussed is GPT; the disease is anemia.